“While the SYNTAX trial suggested
that percutaneous coronary intervention (PCI) with drug-eluting
stents may be safe and effective in selected patients with left
main coronary artery disease, the trial was not powered specifically
to address this set of patients,” said Gregg W. Stone, MD, Professor
of Medicine at Columbia University Medical Center, Director of
Cardiovascular Research and Education at the Center for Interventional
Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University
Medical Center and Co-Director of the Medical Research and Education
Division at the Cardiovascular Research Foundation.
In addition, since the SYNTAX trial, advances have been made drug-eluting
stent technology, PCI procedural guidance, in bypass surgery techniques
and optimal medical therapies. |
